Medline Inc. 8-K

What Happened
Medline Inc. filed an 8-K on May 28, 2026 announcing a refinancing package: the company’s subsidiaries issued $1,250.0 million of 5.000% senior secured notes due 2031 and $750.0 million of 5.250% senior secured notes due 2033 (total $2.0B), and concurrently refinanced an existing term loan with a new senior secured dollar-term loan facility of approximately $2,750.0 million that matures May 28, 2033. Net proceeds from the notes, the new term loan borrowings and cash on hand were used to repay the Issuer’s 2028 term loan in full, refinance about $724.0 million of the 2030 term loan, redeem roughly $500.0 million of 6.250% senior secured notes due 2029, and pay related fees and expenses. Also on May 28, 2026, certain selling stockholders (affiliated with Blackstone, Hellman & Friedman and a subsidiary of the Abu Dhabi Investment Authority) completed an underwritten public sale of 72,554,594 Class A shares at $37.00 per share (with a 30-day option to sell up to an additional 10,883,189 shares).

Key Details

• New notes: $1,250M of 5.000% notes due 6/15/2031 and $750M of 5.250% notes due 6/15/2033; interest paid semi-annually beginning 12/15/2026.
• New term loan: ~ $2,750M facility (matures 5/28/2033); amortizes at an aggregate 1.00% per year of original principal, balance due at maturity; interest at base rate or Term SOFR + margin (Term SOFR floor 0.50%).
• Uses of proceeds: repay 2028 term loan in full, refinance ~$724M of 2030 term loan, redeem ~$500M of 2029 notes, plus fees/expenses.
• Equity sale: 72,554,594 shares sold at $37.00; underwriters have 30-day option for up to 10,883,189 additional shares. Affiliates of Blackstone and Carlyle each own >10% of outstanding stock; Blackstone affiliates received >5% of net proceeds — offering conducted in compliance with FINRA Rule 5121.

Why It Matters
This transaction materially alters Medline’s capital structure by adding $2.0B of fixed-rate secured notes and rolling its term loan to 2033, extending maturities and locking in specified interest costs. The financing repays and refinances near-term obligations and redeems a portion of earlier 2029 notes, which may reduce near-term refinancing risk. The new notes and term loan are secured pari passu with existing secured facilities and include customary covenants and collateral mechanics (including a potential Collateral Release Date tied to an Investment Grade Event). The equity sale was by existing selling stockholders (not a primary issuance by Medline) and involved parties with material ownership stakes, a point addressed under FINRA rules. Investors should note the increased secured debt levels, the fixed interest rates on the new notes, and that certain covenants and collateral protections remain in place until any permitted collateral release.